EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study



Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study



Journal of Clinical Oncology 13(7): 1649-1655



Purpose: To compare the response rates and the toxicity of the new antifolate edatrexate (EDX) with that of methotrexate (MTX) in a randomized trial in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCC) and to compare the durations of response and survival. Patients and Methods: Two hundred seventy-three patients with SCC were randomized to receive either EDX or MTX as a weekly intravenous (IV) bolus injection. Doses of EDX were initially 80 mg/m-2/wk, but because of the toxicity, this was later reduced to 70 mg/m-2/wk. MTX was administered at a dose of 40 mg/m-2/wk throughout. in both arms, two dose increments of 10% were scheduled in case of no toxicity. Results: Of 264 eligible patients, 131 were treated with EDX and 133 with MTX. There were five treatment-related deaths: four on EDX and one on MTX. Overall, toxicity was similar in both arms; however, stomatitis, skin toxicity, and hair loss were more pronounced on the EDX arm. The overall response rate was 21% (six complete responses (CRs) and 21 partial responses (PRs)) for EDX and 16% (nine CRs and 12 PRs) for MTX (P = .392). Responses were mainly seen in patients with lacoregional disease. Tumors that originated from the hypopharynx responded poorly in comparison to tumors from other sites. The median duration of response was 6.1 months for EDX and 6.4 months for MTX (log-rank P = .262). There was no difference in overall or progression-free survival. The median survival duration was 6 months on both treatment groups. Conclusion: Both EDX and MTX are moderately active against SCC. In this large phase III study, response rates, time to treatment failure, and overall survival appeared to be similar for both antifolates. However, EDX had more side effects than MTX and therefore cannot be recommended for routine palliative treatment of patients with SCC.

(PDF emailed within 0-6 h: $19.90)

Accession: 009295898

Download citation: RISBibTeXText

PMID: 7602354

DOI: 10.1200/jco.1995.13.7.1649



Related references

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Annals of Oncology 5(6): 521-526, 1994

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet. Oncology 16(5): 583-594, 2015

A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group. Annals of Oncology 3(3): 223-226, 1992

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. Bmc Cancer 14(): 473-473, 2015

Prospective, randomized comparison of chemotherapy of recurrent or metastatic squamous cancer of the head and neck (SCH&N) with methotrexate (M) versus methotrexate, bleomycin (B) and cis-diamminedichloroplatinum II (D) an Eastern cooperative oncology group study. International Journal of Radiation Oncology*biology*physics 7(Supp-S1): 87-0, 1981

Treatment of recurrent or metastatic squamous cancer of the head and neck with methotrexate methotrexate plus corynebacterium parvum propionibacterium acnes or methotrexate plus bleomycin plus di ammine di chloro platinum a prospective randomized trial of the eastern cooperative oncology group. Proceedings of the American Association for Cancer Research & American Society of Clinical Oncology 22: 532, 1981

EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. Journal of the National Cancer Institute 92(12): 977-986, 2000

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Annals of Oncology 27(8): 1585-1593, 2017

Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. Journal of Clinical Oncology 16(3): 1054-1059, 1998

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Annals of Oncology 19(5): 977-983, 2008

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy. Oncologist 21(12): 1416-1e17, 2016

Iproplatin jm 9 in advanced squamous cell carcinoma of the head and neck a phase ii study of the european organization for research on treatment cancer early clinical trials group. Proceedings American Society of Clinical Oncology Annual Meeting 5: 147, 1986

Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp (R)) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. 2007

Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Annals of Oncology 4(9): 785-788, 1993

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. Journal of the National Cancer Institute 88(13): 890-899, 1996